Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 44

Related Articles by Review for PubMed (Select 14734954)

1.

Health-related quality of life among patients with breast cancer receiving zoledronic acid or pamidronate disodium for metastatic bone lesions.

Weinfurt KP, Castel LD, Li Y, Timbie JW, Glendenning GA, Schulman KA.

Med Care. 2004 Feb;42(2):164-75.

PMID:
14734954
2.

Optimal management of metastatic bone disease.

Major P.

Eur J Oncol Nurs. 2007;11 Suppl 2:S32-7. Epub 2007 Sep 4. Review.

PMID:
17804294
3.

Management of bone metastases in breast cancer.

Lipton A.

Curr Treat Options Oncol. 2005 Mar;6(2):161-71. Review.

PMID:
15717997
4.

Zoledronic acid: a pharmacoeconomic review of its use in the management of bone metastases.

McKeage K, Plosker GL.

Pharmacoeconomics. 2008;26(3):251-68. Review.

PMID:
18282018
6.

Bisphosphonates in breast cancer.

Coleman RE.

Ann Oncol. 2005 May;16(5):687-95. Epub 2005 Mar 31. Review.

7.

The role of bisphosphonates in breast and prostate cancers.

Brown JE, Neville-Webbe H, Coleman RE.

Endocr Relat Cancer. 2004 Jun;11(2):207-24. Review.

8.

Bisphosphonates: reducing the risk of skeletal complications from bone metastasis.

Costa L.

Breast. 2007 Dec;16 Suppl 3:S16-20. Epub 2007 Nov 26. Review.

PMID:
18032044
9.

Bisphosphonates and metastatic breast carcinoma.

Lipton A.

Cancer. 2003 Feb 1;97(3 Suppl):848-53. Review.

10.

Optimizing bisphosphonate therapy in patients with breast cancer on endocrine therapy.

Harvey HA.

Semin Oncol. 2004 Dec;31(6 Suppl 12):23-30. Review.

PMID:
15719598
11.

Evolving role of bisphosphonates in women undergoing treatment for localized and advanced breast cancer.

Gralow J.

Clin Breast Cancer. 2005 Feb;5 Suppl(2):S54-62. Review.

PMID:
15807925
12.

Zoledronic acid : a review of its use in the management of bone metastases of malignancy.

Dhillon S, Lyseng-Williamson KA.

Drugs. 2008;68(4):507-34. Review.

PMID:
18318568
13.

Effect of bisphosphonates on pain and quality of life in patients with bone metastases.

Costa L, Major PP.

Nat Clin Pract Oncol. 2009 Mar;6(3):163-74. doi: 10.1038/ncponc1323. Epub 2009 Feb 3. Review.

PMID:
19190592
14.

Efficacy of clodronate, pamidronate, and zoledronate in reducing morbidity and mortality in cancer patients with bone metastasis: a meta-analysis of randomized clinical trials.

Machado M, Cruz LS, Tannus G, Fonseca M.

Clin Ther. 2009 May;31(5):962-79. doi: 10.1016/j.clinthera.2009.05.009. Review.

PMID:
19539097
15.

Zoledronic acid: a review of its use in breast cancer.

Lyseng-Williamson KA.

Drugs. 2008;68(18):2661-82. doi: 10.2165/0003495-200868180-00010. Review.

PMID:
19093706
16.

Skeletal morbidity in lung cancer patients with bone metastases: demonstrating the need for early diagnosis and treatment with bisphosphonates.

Langer C, Hirsh V.

Lung Cancer. 2010 Jan;67(1):4-11. doi: 10.1016/j.lungcan.2009.08.020. Epub . Review.

PMID:
19939491
17.

Health-related quality-of-life measurement in randomized clinical trials in breast cancer--taking stock.

Goodwin PJ, Black JT, Bordeleau LJ, Ganz PA.

J Natl Cancer Inst. 2003 Feb 19;95(4):263-81. Review.

18.

Zoledronic acid: a review of its use in patients with advanced cancer.

Perry CM, Figgitt DP.

Drugs. 2004;64(11):1197-211. Review.

PMID:
15161327
19.

Clinical and economic issues in the treatment of advanced breast cancer with bisphosphonates.

Liberato NL, Marchetti M, Barosi G.

Drugs Aging. 2003;20(9):631-42. Review.

PMID:
12831288
20.

Breast cancer: bisphosphonate therapy for metastatic bone disease.

Body JJ.

Clin Cancer Res. 2006 Oct 15;12(20 Pt 2):6258s-6263s. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk